白色脂肪细胞衍生出异位体的miR-23b通过准ELF4来调节GLP-1R转录来抑制发热
Qian Wang1, Junkai Du2, Ruili Ma3
1Functional Experiment Center, Department of Basic Medicine, Xi'an Medical University, Xi'an, 710021, China. wangqian@xiyi.edu.cn.
Naunyn-Schmiedeberg's archives of pharmacology
|February 9, 2024
概括
从白色脂肪组织中携带miR-23b的外体因阻碍热生成和脂肪色而加重肥胖症. 这通过准调节GLP-1R的ELF4而发生,从而影响代谢健康.
科学领域:
- 代谢性疾病研究研究.
- 脂肪组织生物学 脂肪组织生物学
- 分子内分泌学分子内分泌学
背景情况:
- 肥胖是一个日益严重的健康问题,与棕色脂肪组织 (BAT) 和白色脂肪组织 (WAT) 色的热生成受损有关.
- 外基因组调解细胞间通信,含有微RNA (miRNA) 的脂肪组织衍生外基因组可能在肥胖中发挥作用.
- 外体miR-23b在调节脂肪组织热生成和肥胖进展方面的特定作用需要进一步研究.
研究的目的:
- 研究来自白色脂肪组织的外体miR-23b在调节非热和肥胖的功能.
- 阐明外体miR-23b影响热生成和脂肪组织色的分子机制.
主要方法:
- 使用高脂肪饮食 (HFD) 建立了一种肥胖的小鼠模型.
- 通过腹腔内注射进行 inguinal WAT (iWAT) 衍生的外体和 miR-23b 抗体.
- 利用了分子生物学技术,包括基因表达分析,mtDNA复制数评估,以及涉及目标基因识别 (Elf4) 和促进体分析 (GLP-1R) 的机制研究.
主要成果:
- 在小鼠中,WAT衍生的外体miR-23b的使用增加了体重,脂肪细胞缩和胰岛素抵抗.
- 外体miR-23b抑制了热生成基因表达,在BAT中进行线粒体生物发生,在冷刺激下进行WAT色.
- 发现miR-23b的目标是Elf4,Elf4反过来调节GLP-1R的转录,从而影响热生成和线粒体呼吸.
结论:
- 来自白色脂肪组织的外体miR-23b通过抑制BAT和WAT色中非的热生成促进肥胖.
- 该机制涉及miR-23b针对Elf4抑制GLP-1R转录,导致热生成能力降低.
- 向外体miR-23b为肥胖和相关代谢障碍提供了潜在的治疗策略.
相关概念视频
Cell Specific Gene Expression
13.6K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.6K
Glucagon-like Receptor Agonists
322
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
322


